Read about our groundbreaking advancements:
- Saponin Derivative and MPLA-Adjuvanted Intranasal Protein Nanoparticle Vaccines Induce Potent Mucosal Immunity and Durable Heterologous Influenza Protection in Mice
- Improving Cytotoxicity of Saporin with Saponin SO1406 Isolated from the Roots of Saponaria Officinalis
- Impact of Side Chain Structure and Aglycon Carbonyl Group on the Immunostimulatory Activities of Semisynthetic Saponin Adjuvants
- VSA-2-, A Novel Plant-Derived Adjuvant for SARS-CoV-2 Subunit Vaccine
- Structure-Activity Relationship Study of Momordica Saponin II Derivatives as Vaccine Adjuvants
- Development of Semisynthetic Saponin Immunostimulants
- Potentiating Pneumococcal Glycoconjugate Vaccine PCV13 with Saponin Adjuvant VSA-1
- Natural and Synthetic Saponins as Vaccine Adjuvants
- Adjuvant Effects of a New Saponin Analog VSA-1 on Enhancing Homologous and heterosubtypic Protection by Influenza Virus Vaccination
- Structural Effect on Adjuvanticity of Saponins
- Impact of C28 Oligosaccharide on Adjuvant Activity of QS-7 Analogues
- Vaccine Adjuvants Derivatized from Momordica Saponins I and II
- Synthesis and Evaluation of a QS-17/18-Based Vaccine Adjuvant
- Synthesis and Evaluation of QS-7-Based Vaccine Adjuvants
- Synthesis and Evaluation of QS-21-Based Immunoadjuvants with a Terminal-Functionalized Side Chain Incorporated in the West Wing Trisaccharide
- Synthesis of QS-21-Based Immunoadjuvants
At Adjuvax, we are dedicated to developing potent, cost-effective, structurally defined, and highly accessible saponin adjuvants with diverse activity profiles tailored to various vaccine applications.
Stay Connected: